NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

February 2010 New Drug Updates and Additions

Designation

Brand Name

Generic Name

GW776C85

Cytefuran

Eniluracil

ADH-1

Exherin

 

3PO, PFKFB3

 

 

4-IPP

 

 

CK37 and analogs

 

 

PU27

 

 

AEG35156/GEM640

 

 

AEG40826, HGS1029

 

 

C2L

 

Octreotide

APR-246, PRIMA-1MET

 

 

AP24534

 

 

ARQ-650RP, ARQ 650RP, ARQ 197, ARQ197

 

 

AZD6244, ARRY-142886, ARRY-886

 

 

BZL101, BZL 101

Bezielle

 

BN108

 

 

XL281

 

 

BMS753493

Epofolate

 

VQD-002, API-2, NSC-154020, VD-0002

 

Triciribine phosphate (TCN-P), triciribine phosphate monohydrate (TCN-PM)

BBR 2778

Pixvuri

Pixantrone

 

Kevetrin

 

CGX-635, NSC-141633

Omapro

Omacetaxine mepesuccinate

VGX-100

 

 

VGX-200 series

 

 

CPI-613

Thioctan

 

COTI-2

 

 

CT-011

 

 

CX-4945/CX-5011

 

 

CYT387

 

 

QbG10, CYT003-QbG10, CYT004-MelQbG10

Immunodrugs

 

CUDC-305, CUDC-0305, Debio 0932

 

 

 

Percutaneous Hepatic Perfusion (PHP)

Melphalan

 

Percutaneous Hepatic Perfusion (PHP)

Doxorubicin

E6201

 

 

DP-3346/DP-2514

 

 

EC20

FolateScan

Vitamin folate

EC145

 

 

EC0225

 

 

EC0489

 

 

EC0531, EC0305

 

 

EC0652

 

 

FG-3019

 

 

FP-1039

 

 

 

Rexonum

Ertumaxomab

 

StemEX

Carlecortemcel-l

XL518, GDC-0973

 

 

GDC-0879

 

 

DJ-927

 

Tesetaxel

SB485232, SB-485232

 

Iboctadekin

GSK1120212

 

 

GSK461364

 

 

HGS-ETR1, HGS1012, TRM1, TRM-1

 

Mapatumumab

IMMU-115, hLL1

 

Milatuzumab

DPX-0907

 

 

KXO1, KX01, KX2-391

 

 

AV-951, formerly KRN951

 

Tivozanib

KW-0761, KM2760

 

 

MT103, MT-103, MEDI-538

 

Blinatumomab

TAK-733

 

 

MP-412, AV-412

 

 

LMB-2 (formerly anti-Tac(Fv)-PE38), NSC-676422

 

 

 

DCVax-Brain

 

CHIR-265, RAF265

 

 

AUY922, CCT018159 and related compounds

 

 

NVP-HSP990

 

 

OMP-21M18

 

 

OTS-102, OTS102

 

 

PX-866, PX866

 

 

PR-171

 

Carfilzomib

HuM291

Nuvion

Visilizumab

CP-336,156

Fablyn

Lasofoxifene

CMC-544, CMC544, PF-5208773

 

Inotuzumab ozogamicin

POL6326

 

 

NX-473, NX 473 (formerly AMD-473, AMD473, ZD0473)

 

Picoplatin

PLX4032, PLX4720, RG7204, RO5185426

 

 

GDC-0941 (formerly PI-103, PI103)

 

 

AV-299, SCH900105

 

 

SNS-595, SPC-595 (formerly AG-7352)

 

Voreloxin

STA-9090

 

 

HuMax-CD4

 

Zanolimumab

PXD101, NSC 726630

 

Belinostat

APO866, FK866

 

 

V158411

 

 

XmAb 2513

 

 

XmAb5574

 

 

XmAb 5485, XmAb5485

 

 

 

Clearazide

Mechlorethamine

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM